Start Losing Weight in Weeks, Sustain it Long-Term 

By Dr. Tiffany Genewick

If you’ve been considering weight loss injections, it’s more important than ever to work with a medical professional like me here in Buffalo. The FDA has issued warnings about unapproved and compounded GLP‑1 drugs—like semaglutide and tirzepatide—being sold falsely online with incorrect labeling, unknown quality, or unsafe dosage instructions.

In contrast, I only provide high-quality and FDA‑approved semaglutide and tirzepatide for my patients. When your weight loss journey is managed under clinical supervision, you benefit from well‑studied safety, precise dosing, ongoing monitoring, and real results. While my patients want to feel their clothes looser as soon as possible, I also work with them on a long-term plan to sustain weight loss over time. It takes time, and it does work.

For example, in real‑world settings with weekly semaglutide treatment, adults with obesity lost body weight reductions of:

~ 3.8% after 4 weeks.

~5.9% at 3 months, and

~10.9% at 6 months, with many patients achieving up to 15% weight loss. Another study showed that in the STEP* trials, semaglutide plus lifestyle changes led to ~15% weight loss after 68 weeks, vs. about 2.4% with lifestyle intervention alone.

When you work with me, I evaluate your medical history, lab results, and weight‐loss goals. We set a safe dose, manage side effects, track progress monthly, and make adjustments as needed. It’s not just about losing weight—it’s about doing it in a safe, sustainable way so your health improves long-term. At my office, we can treat all of you so you feel good both inside and out.

If you’re ready for medically supervised weight loss—semaglutide or tirzepatide injections—let’s talk. You deserve care you can trust and results that last.

*The STEP trials—short for Semaglutide Treatment Effect in People with Obesity—are a series of landmark, large-scale, placebo-controlled clinical studies that evaluated the effectiveness and safety of semaglutide, a GLP‑1 receptor agonist, for chronic weight management in adults.

Sources:

U.S. Food and Drug Administration

The Journal of the American Medical Association

UCLA Health